Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

JANX

Janux Therapeutics Inc

Dec 13 • 03:47PM ET

61.21

Dollar change -0.29
Percentage change -0.47	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN BPMC KURA BLUE ALLO ADAP CARA FATE PTCT AVIR

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.18	Insider Own	18.68%	Shs Outstand	52.34M	Perf Week	-5.82%
Market Cap	3.54B	Forward P/E	-	EPS next Y	-1.89	Insider Trans	-13.07%	Shs Float	47.00M	Perf Month	17.73%
Income	-60.54M	PEG	-	EPS next Q	-0.43	Inst Own	78.35%	Short Float	9.53%	Perf Quarter	22.69%
Sales	13.05M	P/S	271.10	EPS this Y	-6.62%	Inst Trans	-5.72%	Short Ratio	4.75	Perf Half Y	45.74%
Book/sh	12.54	P/B	4.88	EPS next Y	-34.37%	ROA	-11.19%	Short Interest	4.48M	Perf Year	504.84%
Cash/sh	11.38	P/C	5.38	EPS next 5Y	-	ROE	-12.05%	52W Range	7.79 - 71.71	Perf YTD	470.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-92.62%	ROI	-8.93%	52W High	-14.64%	Beta	3.27
Dividend TTM	-	Quick Ratio	38.80	Sales past 5Y	32.66%	Gross Margin	84.07%	52W Low	685.75%	ATR (14)	5.19
Dividend Ex-Date	-	Current Ratio	38.80	EPS Y/Y TTM	20.33%	Oper. Margin	-658.76%	RSI (14)	58.65	Volatility	7.03% 8.22%
Employees	64	Debt/Eq	0.04	Sales Y/Y TTM	54.12%	Profit Margin	-463.91%	Recom	1.27	Target Price	88.08
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-102.92%	Payout	-	Rel Volume	0.42	Prev Close	61.50
Sales Surprise	-70.64%	EPS Surprise	-55.82%	Sales Q/Q	-82.56%	Earnings	Nov 06 AMC	Avg Volume	943.46K	Price	61.21
SMA20	12.48%	SMA50	16.15%	SMA200	31.49%	Trades		Volume	387,144	Change	-0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-24	Reiterated	H.C. Wainwright	Buy	$63 → $70
Dec-03-24	Reiterated	BTIG Research	Buy	$82 → $100
Nov-22-24	Initiated	Leerink Partners	Outperform	$79
Oct-24-24	Initiated	UBS	Buy	$69
Sep-06-24	Initiated	Stifel	Buy	$70
May-30-24	Initiated	Scotiabank	Sector Perform	$47
Mar-21-24	Initiated	BTIG Research	Buy	$62
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight	$100
Apr-06-23	Initiated	Wedbush	Outperform	$24
Nov-14-22	Initiated	William Blair	Outperform

Dec-06-24 07:43PM	Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million (Business Wire) -5.14%
Dec-04-24 11:12PM	Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) +11.65%
06:23PM	Why Janux Therapeutics Crushed the Market Today (Motley Fool)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +48.98%
04:01PM	Janux Therapeutics Announces Proposed Public Offering (Business Wire)
11:58AM	Loading…
11:58AM	Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz (GuruFocus.com)
11:20AM	Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results (Barrons.com)
10:01AM	Janux Skyrockets: 69% Surge This Morning Leads to 650% Gain in a Year (GuruFocus.com)
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
06:13AM	Janux impresses Wall Street with new prostate cancer drug results (BioPharma Dive)
Dec-02-24 04:30PM	Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC (Business Wire) -11.13%
Nov-25-24 09:00AM	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies (Business Wire)
Nov-23-24 06:21AM	Janux Therapeutics initiated with an Outperform at Leerink (TipRanks)
Nov-15-24 08:34PM	Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-06-24 04:01PM	Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
06:33PM	Loading…
Nov-01-24 06:33PM	Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-23-24 09:05PM	Paradigm Biocapital Advisors LP Acquires Shares in Janux Therapeutics Inc (GuruFocus.com)
Oct-22-24 09:07PM	RA Capital Management Reduces Stake in Janux Therapeutics (GuruFocus.com)
Oct-07-24 05:08PM	Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now (Insider Monkey)
Sep-26-24 07:30PM	Is Janux Therapeutics Inc. (JANX) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-20-24 06:39PM	Lennar, Bitdeer, and More Stocks See Action From Activist Investors (Barrons.com)
Sep-17-24 01:30AM	RA Capital Management L.P. Increases Stake in Janux Therapeutics Inc (GuruFocus.com)
Sep-14-24 07:33PM	Janux Therapeutics, Inc. (JANX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-13-24 06:10AM	Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last? (Zacks) +7.48%
Aug-16-24 04:36PM	Southwest Airlines, Rocket Lab USA, and More Stocks See Action From Activist Investors (Barrons.com) +5.08%
Aug-07-24 11:54PM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:15PM	Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
Jul-22-24 04:01PM	Janux Therapeutics Announces Updates to Board of Directors (Business Wire) +6.80%
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
07:05PM	Loading…
Jun-14-24 07:05PM	TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors (Barrons.com)
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire) -6.19%
May-08-24 09:06AM	Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating (MT Newswires) -9.97%
07:32AM	Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates (GuruFocus.com)
May-07-24 10:56PM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
Apr-30-24 08:50AM	Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength (Zacks)
Apr-25-24 11:28AM	11 Oversold MidCap Stocks To Buy Now (Insider Monkey)
Apr-17-24 01:12PM	Take the Money and Run: 3 Overbought Stocks to Sell ASAP (InvestorPlace) -5.12%
Apr-16-24 01:19PM	These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come? (InvestorPlace)
Apr-15-24 12:54PM	Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors (Zacks)
Apr-12-24 08:50AM	Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +5.30%
05:40AM	Why Janux Therapeutics Stock Is Crushing It This Week (Motley Fool)
Apr-11-24 04:19PM	Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily) +12.06%
02:13PM	Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday? (Benzinga)
09:55AM	Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet (Zacks)
09:17AM	Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
Apr-10-24 06:39PM	Why Janux Therapeutics Stock Soared as the Market Sagged Today (Motley Fool) +11.47%
Apr-08-24 09:35AM	After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX) (Zacks) +9.99%
Mar-28-24 12:00PM	Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-22-24 09:55AM	Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade (Zacks)
Mar-20-24 03:44PM	Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst (Benzinga)
Mar-15-24 10:53AM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
09:45AM	2 Stocks That Have More Than Tripled This Year: Are They Buys? (Motley Fool)
Mar-08-24 04:31PM	Janux Therapeutics Inc (JANX) Reports Encouraging Clinical Data and Solid Financial Position ... (GuruFocus.com)
04:01PM	Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-02-24 06:56AM	After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy? (Motley Fool)
Mar-01-24 08:50AM	Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why (Zacks)
Feb-29-24 01:22AM	Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-27-24 05:00PM	Janux Therapeutics Announces Proposed Public Offering of Common Stock (Business Wire) +229.47% -6.34%
04:04PM	Janux Stock Launches 230% On Its 'Significant Opportunity' In Prostate Cancer Treatment (Investor's Business Daily)
10:07AM	Janux Therapeutics Nearly Triples As Prostate Cancer Drug Shows 'Significant Opportunity' (Investor's Business Daily)
07:46AM	Why Is Janux Therapeutics (JANX) Stock Up 108% Today? (InvestorPlace)
07:15AM	Janux shares triple on early cancer immunotherapy data (BioPharma Dive)
Feb-26-24 04:05PM	Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors (Business Wire)
Feb-21-24 02:39AM	Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last? (Zacks) +31.93%
Feb-20-24 08:00AM	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 (Business Wire) +5.62%
Jan-08-24 09:00AM	Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer (Business Wire)
Dec-01-23 09:55AM	Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect? (Zacks)
Nov-15-23 09:55AM	Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High? (Zacks) +5.40%
Nov-10-23 09:35AM	Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-07-23 04:01PM	Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-10-23 09:55AM	Wall Street Analysts Think Janux Therapeutics, Inc. (JANX) Could Surge 120.82%: Read This Before Placing a Bet (Zacks)
Aug-08-23 05:40PM	Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +6.82%
04:01PM	Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire)
Jul-20-23 12:00PM	All You Need to Know About Janux Therapeutics, Inc. (JANX) Rating Upgrade to Buy (Zacks)
09:55AM	Wall Street Analysts Believe Janux Therapeutics, Inc. (JANX) Could Rally 120.65%: Here's is How to Trade (Zacks)
06:40AM	Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Could Be 28% Below Their Intrinsic Value Estimate (Simply Wall St.)
Jul-17-23 08:45AM	Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire)
08:00AM	Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs (Business Wire)
Jun-05-23 04:35PM	Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development (Business Wire)
10:38AM	Shareholders have faith in loss-making Janux Therapeutics (NASDAQ:JANX) as stock climbs 20% in past week, taking one-year gain to 29% (Simply Wall St.)
May-09-23 05:15PM	Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-02-23 10:01AM	Analysts Estimate Janux Therapeutics, Inc. (JANX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-24-23 04:01PM	Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences (Business Wire)
Apr-20-23 04:01PM	Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors (Business Wire)
Apr-05-23 10:22AM	Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace) -6.34%
Mar-10-23 04:01PM	Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Feb-14-23 12:00PM	Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference (Business Wire) -8.62%
Feb-10-23 05:30AM	Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Could Be 22% Above Their Intrinsic Value Estimate (Simply Wall St.)
Jan-10-23 12:00PM	Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +5.75%
Dec-27-22 09:00AM	Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors (Business Wire)
08:51AM	Janux Therapeutics (NASDAQ:JANX) investors are sitting on a loss of 44% if they invested a year ago (Simply Wall St.)
Nov-23-22 09:55AM	Here's Why Janux Therapeutics, Inc. (JANX) Looks Ripe for Bottom Fishing (Zacks)
Nov-22-22 06:00AM	Janux Therapeutics to Present at Upcoming Investor Conferences in November (Business Wire)
Nov-21-22 12:22PM	7 Short-Squeeze Stocks for Bold Contrarians to Consider (InvestorPlace)

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Campbell David Alan	President and CEO	Dec 03 '24	Sale	67.00	15,000	1,005,000	242,054	Dec 03 08:00 PM
Campbell David Alan	President and CEO	Nov 25 '24	Sale	51.60	25,000	1,289,879	257,054	Nov 27 08:00 PM
Reardon Tighe	FORMER OFFICER	Nov 01 '24	Proposed Sale	53.44	5,202	277,987		Nov 01 05:05 PM
Lichter Jay	FORMER DIRECTOR	Nov 01 '24	Proposed Sale	53.31	1,139	60,723		Nov 01 05:02 PM
Avalon Ventures XI, L.P.	10% Owner	Nov 01 '24	Proposed Sale	53.66	56,440	3,028,665		Nov 01 04:30 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Nov 01 '24	Proposed Sale	53.66	57,627	3,092,362		Nov 01 04:24 PM
Avalon BioVentures I, LP	10% Owner	Nov 01 '24	Proposed Sale	53.66	10,934	586,731		Nov 01 04:17 PM
Reardon Tighe	Former officer	Nov 01 '24	Proposed Sale	52.99	2,999	158,910		Nov 01 04:07 PM
Campbell David Alan	President and CEO	Oct 28 '24	Sale	53.54	25,000	1,338,559	282,054	Oct 30 07:30 PM
Reardon Tighe	FORMER OFFICER	Oct 28 '24	Proposed Sale	53.41	15,122	807,666		Oct 28 05:07 PM
Lichter Jay	FORMER DIRECTOR	Oct 28 '24	Proposed Sale	53.51	3,419	182,954		Oct 28 05:01 PM
Reardon Tighe	Former officer	Oct 28 '24	Proposed Sale	53.36	9,061	483,520		Oct 28 04:46 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 25 '24	Proposed Sale	53.33	169,320	9,029,544		Oct 25 04:57 PM
Avalon BioVentures I, LP	10% Owner	Oct 25 '24	Proposed Sale	53.33	32,800	1,749,162		Oct 25 04:51 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Oct 25 '24	Proposed Sale	53.33	172,880	9,219,392		Oct 25 04:44 PM
Lichter Jay	FORMER DIRECTOR	Oct 24 '24	Proposed Sale	53.37	4,921	262,653		Oct 24 05:53 PM
Reardon Tighe	FORMER OFFICER	Oct 24 '24	Proposed Sale	5.28	217,690	1,148,928		Oct 24 05:04 PM
Lichter Jay	10% Owner	Sep 13 '24	Option Exercise	17.29	3,815	65,951	10,815	Oct 24 04:15 PM
Lichter Jay	10% Owner	Sep 13 '24	Sale	46.68	3,815	178,084	7,000	Oct 24 04:15 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Oct 23 '24	Proposed Sale	51.23	248,797	12,745,011		Oct 23 05:59 PM
Avalon BioVentures I, LP	10% Owner	Oct 23 '24	Proposed Sale	51.23	47,203	2,418,041		Oct 23 05:38 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 23 '24	Proposed Sale	51.23	243,672	12,482,475		Oct 23 05:07 PM
Reardon Tighe	Former officer	Oct 23 '24	Proposed Sale	51.01	13,039	665,094		Oct 23 04:36 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 18 '24	Buy	44.75	1,200,000	53,700,000	9,317,246	Oct 22 04:20 PM
Reardon Tighe	FORMER OFFICER	Oct 21 '24	Proposed Sale	49.43	10,769	532,310		Oct 21 04:43 PM
Reardon Tighe	Former officer	Oct 21 '24	Proposed Sale	50.21	6,324	317,544		Oct 21 04:25 PM
Lichter Jay	FORMER DIRECTOR	Oct 21 '24	Proposed Sale	49.49	2,434	120,454		Oct 21 01:39 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 16 '24	Option Exercise	18.07	10,515	190,031	17,402	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 17 '24	Option Exercise	18.08	1,769	31,979	8,214	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 18 '24	Sale	45.76	801,751	36,691,728	401,321	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 18 '24	Sale	45.76	660,018	30,205,389	2,071,799	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 16 '24	Sale	49.99	108,906	5,444,479	529,173	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 16 '24	Sale	50.08	100,610	5,038,589	6,445	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 17 '24	Sale	50.02	1,843	92,187	6,371	Oct 18 06:51 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 18 '24	Proposed Sale	50.38	118,194	5,954,737		Oct 18 04:57 PM
Avalon BioVentures I, LP	10% Owner	Oct 18 '24	Proposed Sale	50.38	22,895	1,153,468		Oct 18 04:48 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Oct 18 '24	Proposed Sale	50.38	120,680	6,079,984		Oct 18 04:39 PM
Reardon Tighe	FORMER OFFICER	Oct 17 '24	Proposed Sale	50.01	8,158	408,020		Oct 17 05:06 PM
Lichter Jay	FORMER DIRECTOR	Oct 17 '24	Proposed Sale	50.05	1,842	92,193		Oct 17 04:24 PM
Reardon Tighe	Former officer	Oct 17 '24	Proposed Sale	49.67	4,784	237,606		Oct 17 04:18 PM
Reardon Tighe	FORMER OFFICER	Oct 16 '24	Proposed Sale	50.78	48,462	2,460,829		Oct 16 06:14 PM
Avalon BioVentures I, LP	10% Owner	Oct 16 '24	Proposed Sale	49.96	17,367	867,595		Oct 16 05:35 PM
Lichter Jay	FORMER DIRECTOR	Oct 16 '24	Proposed Sale	50.80	10,957	556,599		Oct 16 05:28 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Oct 16 '24	Proposed Sale	49.96	91,539	4,572,999		Oct 16 05:25 PM
Avalon Ventures XI, L.P.	10% Owner	Oct 16 '24	Proposed Sale	49.96	89,653	4,478,780		Oct 16 05:17 PM
Reardon Tighe	Former officer	Oct 16 '24	Proposed Sale	51.34	28,993	1,488,403		Oct 16 05:10 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 27 '24	Option Exercise	18.07	1,752	31,652	8,752	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 30 '24	Option Exercise	18.07	919	16,608	7,845	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 26 '24	Sale	47.23	109,700	5,180,839	555,727	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 26 '24	Sale	47.23	90,300	4,264,629	2,868,875	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 27 '24	Sale	46.46	57,590	2,675,750	546,540	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 27 '24	Sale	46.45	49,231	2,286,878	6,926	Sep 30 08:49 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 30 '24	Sale	46.24	958	44,298	6,887	Sep 30 08:49 PM
Lichter Jay	FORMER DIRECTOR	Sep 30 '24	Proposed Sale	46.24	958	44,302		Sep 30 05:34 PM
Reardon Tighe	FORMER OFFICER	Sep 30 '24	Proposed Sale	46.61	4,493	209,407		Sep 30 05:29 PM
Reardon Tighe	Former Officer	Sep 30 '24	Proposed Sale	46.04	2,537	116,803		Sep 30 04:08 PM
Meyer Andrew Hollman	Chief Business Officer	Sep 27 '24	Option Exercise	4.21	50,000	210,500	117,592	Sep 27 07:32 PM
Meyer Andrew Hollman	Chief Business Officer	Sep 27 '24	Sale	45.96	50,000	2,297,755	67,592	Sep 27 07:32 PM
DiRaimondo Thomas	Chief Scientific Officer	Sep 27 '24	Sale	46.34	5,000	231,716	97,938	Sep 27 07:31 PM
Campbell David Alan	President and CEO	Sep 27 '24	Sale	46.31	25,000	1,157,641	307,054	Sep 27 07:30 PM
Reardon Tighe	FORMER OFFICER	Sep 27 '24	Proposed Sale	45.92	7,812	358,755		Sep 27 06:31 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Sep 27 '24	Proposed Sale	46.43	48,403	2,247,248		Sep 27 05:05 PM
Lichter Jay	FORMER DIRECTOR	Sep 27 '24	Proposed Sale	46.19	1,826	84,335		Sep 27 04:54 PM
Avalon BioVentures I, LP	10% Owner	Sep 27 '24	Proposed Sale	46.43	9,187	426,527		Sep 27 04:51 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 27 '24	Proposed Sale	46.43	47,405	2,200,913		Sep 27 04:51 PM
THOMAS DIRAIMONDO	Officer	Sep 27 '24	Proposed Sale	46.62	5,000	233,100		Sep 27 04:24 PM
Reardon Tighe	Former officer	Sep 27 '24	Proposed Sale	46.18	4,832	223,158		Sep 27 04:18 PM
Campbell David Alan	Officer	Sep 27 '24	Proposed Sale	48.33	90,000	4,350,000		Sep 27 04:05 PM
ANDY MEYER	Officer	Sep 27 '24	Proposed Sale	45.96	50,000	2,297,755		Sep 27 04:01 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 26 '24	Proposed Sale	47.19	90,300	4,260,861		Sep 26 05:57 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Sep 26 '24	Proposed Sale	47.19	92,200	4,350,513		Sep 26 05:35 PM
Avalon BioVentures I, LP	10% Owner	Sep 26 '24	Proposed Sale	47.19	17,500	825,743		Sep 26 05:13 PM
Lichter Jay	FORMER DIRECTOR	Sep 13 '24	Proposed Sale	46.68	3,815	178,084		Sep 13 05:01 PM
Avalon BioVentures I, LP	10% Owner	Sep 12 '24	Proposed Sale	47.00	30,613	1,438,811		Sep 12 09:18 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Sep 12 '24	Proposed Sale	47.00	161,356	7,583,732		Sep 12 09:07 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 12 '24	Proposed Sale	47.00	158,031	7,427,757		Sep 12 08:54 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 12 '24	Sale	47.00	191,969	9,022,543	573,227	Sep 12 08:42 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 12 '24	Sale	47.00	158,031	7,427,457	2,959,175	Sep 12 08:42 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 10 '24	Sale	46.53	55,446	2,579,823	603,840	Sep 12 08:42 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 10 '24	Sale	46.53	45,645	2,123,797	3,117,206	Sep 12 08:42 PM
Reardon Tighe	FORMER OFFICER	Sep 12 '24	Proposed Sale	47.42	15,223	721,932		Sep 12 06:23 PM
Avalon BioVentures I, LP	10% Owner	Sep 10 '24	Proposed Sale	45.52	8,842	402,487		Sep 10 06:32 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Sep 10 '24	Proposed Sale	45.52	46,604	2,121,414		Sep 10 06:26 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 10 '24	Proposed Sale	45.52	45,645	2,077,760		Sep 10 06:22 PM
Reardon Tighe	FORMER OFFICER	Sep 10 '24	Proposed Sale	45.47	3,304	150,239		Sep 10 05:51 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 09 '24	Option Exercise	18.03	2,099	37,838	9,182	Sep 10 05:02 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 06 '24	Sale	42.00	131,635	5,528,670	612,682	Sep 10 05:02 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 06 '24	Sale	42.00	108,365	4,551,330	3,162,851	Sep 10 05:02 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 09 '24	Sale	42.33	2,182	92,364	7,000	Sep 10 05:02 PM
Reardon Tighe	Former officer	Sep 10 '24	Proposed Sale	46.50	2,055	95,554		Sep 10 04:13 PM
Lichter Jay	FORMER DIRECTOR	Sep 09 '24	Proposed Sale	42.33	2,182	92,369		Sep 09 06:09 PM
Reardon Tighe	FORMER OFFICER	Sep 09 '24	Proposed Sale	42.15	9,269	390,691		Sep 09 06:03 PM
Reardon Tighe	Former officer	Sep 09 '24	Proposed Sale	42.12	5,762	242,707		Sep 09 02:28 PM
Avalon BioVentures I, LP	10% Owner	Sep 06 '24	Proposed Sale	41.26	20,991	866,088		Sep 06 07:17 PM
Avalon BioVentures SPV I, L.P.	10% Owner	Sep 06 '24	Proposed Sale	41.26	110,644	4,565,171		Sep 06 07:14 PM
Avalon Ventures XI, L.P.	10% Owner	Sep 06 '24	Proposed Sale	41.26	108,365	4,471,139		Sep 06 07:11 PM
Lichter Jay	Director	Jun 03 '24	Sale	54.75	1,500,000	82,125,000	633,673	Jun 05 07:25 PM
Reardon Tighe	Acting Chief Financial Officer	Jun 03 '24	Sale	54.75	822,721	45,043,975	633,673	Jun 05 07:23 PM
Avalon Ventures XI, L.P.	10% Owner	Jun 03 '24	Sale	54.75	822,721	45,043,975	633,673	Jun 05 07:19 PM
Avalon Ventures XI, L.P.	10% Owner	Jun 03 '24	Sale	54.75	677,279	37,081,025	3,271,216	Jun 05 07:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JANX

Janux Therapeutics Inc

Upgrade your FINVIZ experience